Exact Sciences
Exact Sciences Releases Next-Gen Cologuard Data, Inks New Partnerships
The firm said the new version of its colon cancer screening test improved upon its predecessor across a variety of metrics, including both sensitivity and specificity.
Industry Groups Form European Coalition to Push for Better Comprehensive Genomic Profiling Access
A coalition of a trade group and drugmakers and diagnostics firms aims to share best practices and recommendations for better test reimbursement and uptake.
Exact Sciences Reports 24 Percent Spike in Q1 Revenues, Ups Full-Year Revenue Guidance
Exact reported revenues of $602.5 million compared to $486.6 million a year ago, surpassing analysts' average estimate of $543.5 million.
Vigil Neuroscience Launches No-Cost Genetic Counseling, Testing Program for Rare Neurologic Disorder
The firm is partnering with InformedDNA and PreventionGenetics to improve diagnosis of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
UBS Initiates Coverage of Exact Sciences, Natera, Guardant Health
The investment bank gave Natera and Guardant Health a Buy rating and Exact Sciences a Neutral rating.